Nia Therapeutics announced today that it received FDA breakthrough device designation for its Smart Neurostimulation System (SNS).

Insulet estimates that the pods involved in this correction represent approximately 1.5% of annual production globally.

The FDA approved a new Lantheus prostate cancer imaging agent. South Carolina's measles cases rise. Medtronic's MiniMed shares drop in Nasdaq debut. A French probe exonerates Nestle in a baby death ...

DexCom is also increasingly targeting non-diabetic patients, notably with newer over-the-counter products in the U.S. such as Stelo, which received clearance in 2024 and has attracted over half a ...

Dexcom will stop producing G6 CGM sensors July 1, 2026, urging patients to switch to the smaller, more accurate G7 model.

The Citizens Life Sciences Conference 2026 March 11, 2026 1:05 PM EDTCompany ParticipantsDavid Pacitti - CEO & ...

Stratasys Ltd. ( SSYS) Q4 2025 Earnings Call March 5, 2026 8:30 AM EST ...

MiniMed Flex is a smartphone-controlled insulin pump about half the size of MiniMed’s previous device. It’s the company’s ...

Medtronic and GE HealthCare inked a multiyear deal to expand their more than three-decade- long partnership that aims to boost clinical and technology innovation.

Shares drop 2.6% despite beating quarterly expectations Company expects $300 million hit from tariffs in fiscal 2027 CEO says Danaher-Masimo deal will not change patient-monitoring market long term ...

Neuroscience Portfolio revenue of $2.558 billion, an increase of 4.1% reported and 2.5% organic, with a mid-single digit increase in Neuromodulation, a mid-single digit increase in Cranial & Spinal ...

Medtronic stock at a glance after recent performance Medtronic (MDT) has seen a 0.4% gain over the past day, while returns over the past week, month, and past 3 months have been negative, creating a ...